Defining drug/drug class refractoriness vs lines of therapy in relapsed/refractory multiple myeloma.
Utkarsh GoelCharalampos CharalampousPrashant KapoorMoritz BinderFrancis K BuadiDavid DingliAngela DispenzieriAmie FonderMorie A GertzWilson I GonsalvesSuzanne R HaymanMiriam A HobbsYi L HwaTaxiarchis V KourelisMartha Q LacyNelson LeungYi LinRahma M WarsameRobert A KyleSundararajan Vincent RajkumarShaji K KumarPublished in: Blood cancer journal (2023)